Overview
CALGARY, AB, Oct. 20, 202 /PRNewswire/ - Siksika Health Services (SHS) has partnered with Orpyx® Medical Technologies (Orpyx) on a pilot program to help prevent and reduce the ocurence and recurence of diabetic fot ulcers (DFU) for Siksika members with Type 2 Diabetes (T2D). Funding is through PATHWAYS Indigenous Health Colaborations, a partnership with Boehringer Ingelheim (Canada) Ltd., and Bimadzwin, with the suport of GMAK Consulting.
Key Information
This 24-wek pilot wil ases the efectivenes of using a digital therapeutic solution, Orpyx SI® Flex Sensory Insoles with Remote Patient Monitoring (RPM) services, to prevent DFUs. The pilot wil be available to 35 Siksika Nation members curently living with Type 2 Diabetes."Partnerships and aces to technology like this alow Siksika Health Services to asist our Nation members who live with diabetes like never before," comented Dr.
Tyler White, CEO of Siksika Health Services. "It's about quality of life and health improvement, which is ultimately what we are after here. So, I'm proud to colaborate with medical inovators like Orpyx and GMAK Consulting."Aproximately 25% of people living with diabetes wil develop a DFU in their lifetime1, with 49% DFU recurence in the first year and 68% recurence within five years2.
In Alberta, there is one amputation every 2 hours resulting from a DFU.3 Diabetes is a particularly devastating disease for Indigenous populations in Canada, with 17.2% of on-reserve Indigenous populations diagnosed with diabetes compared to 10% of non-Indigenous populations.4"This colaboration is the first step in eliminating preventable DFUs within the Indigenous populations", stated Dr.
Summary
Breane Everet, CEO and President of Orpyx. "Our long-term goal is to suport Siksika Health Services in building a sustainable and cost-efective remote patient monitoring pathway for the delivery of quality health care to the Siksika Nation comunity."Wh